



LAWRENCE  
LIVERMORE  
NATIONAL  
LABORATORY

UCRL-TR-227807

# adendum for )6 report

Mariella, Ray, Borucki, M, Miles, R, Clague, D,  
Dougherty, G, Fisher, K

February 6, 2007

## **Disclaimer**

---

This document was prepared as an account of work sponsored by an agency of the United States government. Neither the United States government nor Lawrence Livermore National Security, LLC, nor any of their employees makes any warranty, expressed or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States government or Lawrence Livermore National Security, LLC. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States government or Lawrence Livermore National Security, LLC, and shall not be used for advertising or product endorsement purposes.

This work performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344.

This work performed under the auspices of the U.S. Department of Energy by Lawrence Livermore National Laboratory under Contract DE-AC52-07NA27344.

**Addendum for:**

**Engineering**

**FY05 LDRD-ER**

**FY06 Report**

**Rapid Defense Against The Next-Generation Biothreat**

**Principal Investigator:** Raymond Mariella Jr.

**Co-Investigator:** Monica Borucki

**Tracking Code:** 05-ERD-084

**Primary COW:** Advanced Sensors and Instrumentation

**Annual Report Authors:** R. Mariella Jr.; M. Borucki, R. Miles, D. Clague, G. Dougherty, K. Fisher

**FY07 Proposed Work**

Prior to using human nasopharyngeal samples, we will use prepared mixtures of viruses with bacteria and eukaryotic cells in our research on microfluidic separation techniques. Some examples of these mixtures are the bacteriophage MS2 with its host bacteria, *E. coli*, and BSL-1, Risk-Group-1 virus such as fowlpox virus vaccine with its host cell, DF-1, derived from chickens.